ICCC Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
10.4M
+35.8%
7.6M
+38.5%
5.5M
-14.6%
6.4M
-20.1%
8.1M
Cost of Revenue
5.7M
+20.9%
4.7M
+50.0%
3.1M
-13.3%
3.6M
-23.0%
4.7M
Gross Profit
4.7M
+60.0%
2.9M
+23.2%
2.4M
-16.1%
2.8M
-16.0%
3.4M
Operating Expenses
2.7M
-9.4%
3.0M
+26.7%
2.3M
+4.2%
2.2M
+0.5%
2.2M
R&D
317.7K
-58.1%
758.9K
+9.3%
694.3K
-16.5%
831.9K
+9.9%
756.8K
SG&A
2.4M
+7.3%
2.2M
+34.0%
1.6M
+16.4%
1.4M
-4.3%
1.5M
Operating Income
2.0M
+3498.0%
-57956
-388.7%
20.1K
-96.5%
569.6K
-49.0%
1.1M
EBITDA
2.5M
+285.2%
648.4K
-7.3%
699.2K
-43.5%
1.2M
-31.0%
1.8M
Net Income
1.9M
+168.1%
-2849142
-1938.8%
-139748
-127.8%
501.9K
-65.3%
1.4M
EPS (Basic)
$0.21
+167.7%
$-0.31
-1450.0%
$-0.02
-133.3%
$0.06
-62.5%
$0.16
EPS (Diluted)
$0.21
+167.7%
$-0.31
-1450.0%
$-0.02
-133.3%
$0.06
-62.5%
$0.16
Shares (Diluted)
9.0M
-0.0%
9.0M
+0.0%
9.0M
+0.2%
9.0M
+0.6%
9.0M
Immucell (ICCC) โ€” Financials